ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      85.265
      0.18%
      Bitcoin
      63,304.03
      1.01%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      10/02/20215:15AMBusiness WireIncyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With VitiligoNASDAQ:INCYIncyte Corporation
      09/30/20217:03AMDow Jones NewsLilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 WeeksNASDAQ:INCYIncyte Corporation
      09/30/20215:56AMPR Newswire (US)OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia AreataNASDAQ:INCYIncyte Corporation
      09/29/20216:20PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      09/29/20216:07PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:INCYIncyte Corporation
      09/28/20215:00PMBusiness WireIncyte Names New Member to Its Board of DirectorsNASDAQ:INCYIncyte Corporation
      09/28/20214:48PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      09/27/20216:00AMPR Newswire (US)Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic DiseasesNASDAQ:INCYIncyte Corporation
      09/23/20217:30AMGlobeNewswire Inc.Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin AmericaNASDAQ:INCYIncyte Corporation
      09/22/20211:56PMDow Jones NewsIncyte Says FDA Approves Jakafi in Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      09/22/202112:38PMBusiness WireIncyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)NASDAQ:INCYIncyte Corporation
      09/21/20214:13PMBusiness WireIncyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)NASDAQ:INCYIncyte Corporation
      09/21/20214:10PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      09/17/20214:00PMPR Newswire (Canada)Incyte annonce l'approbation conditionnelle par Santé Canada du Pemazyre(MD) (pemigatinib) comme premier traitement ciblé pour les adultes atteints d'un cholangiocarcinome localement avancé ou métastatique, inopérable et déjà traitéNASDAQ:INCYIncyte Corporation
      09/17/20214:00PMPR Newswire (Canada)Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic CholangiocarcinomaNASDAQ:INCYIncyte Corporation
      09/14/20215:29AMBusiness WireIncyte: Daten zu Ruxolitinib-Creme werden auf virtuellem Kongress der Europäischen Akademie für Dermatologie und Venerologie EADV 2021 präsentiertNASDAQ:INCYIncyte Corporation
      09/14/20215:27AMBusiness WireIncyte annonce que des données relatives à la crème au ruxolitinib ont été acceptées pour présentation au congrès virtuel 2021 de l’Académie européenne de dermatologie et de vénérologie (EADV)NASDAQ:INCYIncyte Corporation
      09/13/20214:30PMBusiness WireIncyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual CongressNASDAQ:INCYIncyte Corporation
      09/03/20217:41AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      08/27/202112:47PMBusiness WireIncyte et MorphoSys annoncent l'approbation par la Commission européenne de Minjuvi® (tafasitamab) en association avec le lénalidomide comme traitement pour les patients atteints de lymphome diffus à grandes cellules B (LDGCB) ...NASDAQ:INCYIncyte Corporation
      08/27/20216:05AMBusiness WireIncyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi® (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...NASDAQ:INCYIncyte Corporation
      08/26/20214:01PMBusiness WireIncyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell LymphomaNASDAQ:INCYIncyte Corporation
      08/24/20219:16AMDow Jones NewsIncyte: Canada Approves Minjuvi in Combination With Lenalidomide for LymphomaNASDAQ:INCYIncyte Corporation
      08/24/20218:30AMPR Newswire (Canada)Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaNASDAQ:INCYIncyte Corporation
      08/24/20218:30AMPR Newswire (Canada)Incyte annonce l'approbation par Santé Canada de Minjuvi(MD) (tafasitamab) en association avec la lénalidomide pour le traitement des adultes atteints d'un lymphome diffus à grandes cellules B (LDGCB) récidivant ou réfractaireNASDAQ:INCYIncyte Corporation
      08/20/20214:02PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      08/17/20218:00AMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      08/16/20217:00PMBusiness WireIncyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater ChinaNASDAQ:INCYIncyte Corporation
      08/04/20214:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      08/03/20214:05PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY